This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albini, A. Articles by Noonan, D. M. Search for Related Content PubMed PubMed Citation Articles by Albini, A. Articles by Noonan, D. M. Related Collections Review Tumor Biology Oncogenesis: Animal Models Tumor Biology: Inflammation and Immune Escape Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms

Tumor Inflammatory Angiogenesis and Its Chemoprevention

¹ National Institute for Research on Cancer (IST), Genoa, Italy and ² Università degli Studi dell'Insubria, Varese, Italy

Requests for reprints: Adriana Albini, Molecular Oncology Laboratory, National Cancer Research Institute, Largo Rosanna Benzi 10, 16132 Genoa, Italy. Phone: 39-105-737-7367; Fax: 39-105-737-7231; E-mail: adriana.albini{at}istge.it.

The importance of angiogenesis for the growth of tumors is widely recognized. Drugs that successfully target the endothelium, such as antivascular endothelial growth factor antibodies, are beginning to have an effect on the life expectancy of cancer patients. However, the endothelial cell is not the only possible target for antiangiogenic therapy or prevention of vascularization (angioprevention). It is evident from the literature that native immune cells recruited into tumors in turn stimulate the endothelium and are responsible for an indirect pathway of tumor vascularization. Inflammation-dependent angiogenesis seems to be a central force in tumor growth and expansion, a concept supported by the observation that the use of "classic" anti-inflammatory drugs, such as nonsteroidal anti-inflammatory drugs, leads to angiogenesis inhibition. The mechanisms of inflammatory angiogenesis provide new approaches to target, cure, or even better, prevent tumor angiogenesis by treatment with synthetic or natural agents with anti-inflammatory properties. We propose chemoprevention of inflammatory angiogenesis as a way of checking the cancer before it progresses.

This article has been cited by other articles:

				A. C. Straub, L. R. Klei, D. B. Stolz, and A. Barchowsky Arsenic Requires Sphingosine-1-Phosphate Type 1 Receptors to Induce Angiogenic Genes and Endothelial Cell Remodeling Am. J. Pathol., May 1, 2009; 174(5): 1949 - 1958. [Abstract] [Full Text] [PDF]

				H. Sun, W.-C. Chung, S.-H. Ryu, Z. Ju, H. T. Tran, E. Kim, J. M. Kurie, and J. S. Koo Cyclic AMP-Responsive Element Binding Protein- and Nuclear Factor-{kappa}B-Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis Cancer Prevention Research, October 1, 2008; 1(5): 316 - 328. [Abstract] [Full Text] [PDF]

				L. Wang, G.-G. Zheng, C.-H. Ma, Y.-M. Lin, H.-Y. Zhang, Y.-Y. Ma, J.-H. Chong, and K.-F. Wu A Special Linker between Macrophage and Hematopoietic Malignant Cells: Membrane Form of Macrophage Colony-Stimulating Factor Cancer Res., July 15, 2008; 68(14): 5639 - 5647. [Abstract] [Full Text] [PDF]

				K. Liby, R. Risingsong, D. B. Royce, C. R. Williams, M. M. Yore, T. Honda, G. W. Gribble, W. W. Lamph, N. Vannini, I. Sogno, et al. Prevention and Treatment of Experimental Estrogen Receptor-Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268 Clin. Cancer Res., July 15, 2008; 14(14): 4556 - 4563. [Abstract] [Full Text] [PDF]

				Y. Sawanobori, S. Ueha, M. Kurachi, T. Shimaoka, J. E. Talmadge, J. Abe, Y. Shono, M. Kitabatake, K. Kakimi, N. Mukaida, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice Blood, June 15, 2008; 111(12): 5457 - 5466. [Abstract] [Full Text] [PDF]

				R. T. van Beem, W. A. Noort, C. Voermans, M. Kleijer, A. ten Brinke, S. M. van Ham, C. E. van der Schoot, and J. J. Zwaginga The Presence of Activated CD4+ T Cells Is Essential for the Formation of Colony-Forming Unit-Endothelial Cells by CD14+ Cells J. Immunol., April 1, 2008; 180(7): 5141 - 5148. [Abstract] [Full Text] [PDF]

				T. Yi, Z. Yi, S.-G. Cho, J. Luo, M. K. Pandey, B. B. Aggarwal, and M. Liu Gambogic Acid Inhibits Angiogenesis and Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2 Signaling Cancer Res., March 15, 2008; 68(6): 1843 - 1850. [Abstract] [Full Text] [PDF]

				P. Secchiero, F. Corallini, E. Rimondi, C. Chiaruttini, M. G. di Iasio, A. Rustighi, G. Del Sal, and G. Zauli Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells Blood, February 1, 2008; 111(3): 1287 - 1294. [Abstract] [Full Text] [PDF]

				N. Vannini, G. Lorusso, R. Cammarota, M. Barberis, D. M. Noonan, M. B. Sporn, and A. Albini The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent Mol. Cancer Ther., December 1, 2007; 6(12): 3139 - 3146. [Abstract] [Full Text] [PDF]

				S. M. Lippman and J. V. Heymach The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention Clin. Cancer Res., July 15, 2007; 13(14): 4035 - 4041. [Abstract] [Full Text] [PDF]

				C. P. Matthews, A. M. Birkholz, A. R. Baker, C. M. Perella, G. R. Beck Jr., M. R. Young, and N. H. Colburn Dominant-Negative Activator Protein 1 (TAM67) Targets Cyclooxygenase-2 and Osteopontin under Conditions in which It Specifically Inhibits Tumorigenesis Cancer Res., March 15, 2007; 67(6): 2430 - 2438. [Abstract] [Full Text] [PDF]

				Speakers' abstracts Ann Rheum Dis, March 1, 2007; 66(suppl_1): A1 - A5. [Full Text] [PDF]

				C. D. Davis Nutritional Interactions: Credentialing of Molecular Targets for Cancer Prevention Experimental Biology and Medicine, February 1, 2007; 232(2): 176 - 183. [Abstract] [Full Text] [PDF]

				R. Dell'Eva, C. Ambrosini, S. Minghelli, D. M. Noonan, A. Albini, and N. Ferrari The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-{kappa}B pathway Carcinogenesis, February 1, 2007; 28(2): 404 - 413. [Abstract] [Full Text] [PDF]

				F. Tosetti, D. M. Noonan, and A. Albini Choking hypoxia-inducible factor 1alpha: a novel mechanism for connective tissue growth factor inhibition of angiogenesis. J Natl Cancer Inst, July 19, 2006; 98(14): 946 - 948. [Full Text] [PDF]

				R. Schindler and R. Mentlein Flavonoids and Vitamin E Reduce the Release of the Angiogenic Peptide Vascular Endothelial Growth Factor from Human Tumor Cells J. Nutr., June 1, 2006; 136(6): 1477 - 1482. [Abstract] [Full Text] [PDF]